Aurobindo Pharma Q2 Results FY27: Revenue Up 23.87% YoY, Net Profit Up 32.51%, Revenue Rs 10,263.29 Cr, PAT Rs 1,123.84 Cr
- November 4, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Aurobindo Pharma Q2 Results FY27 were declared on 4 November 2026, and the quarterly results show consolidated revenue of Rs 10,263.29 Cr, up 23.87% YoY from Rs 8,285.70 Cr. Net profit rose 32.51% YoY to Rs 1,123.84 Cr from Rs 848.13 Cr. Operating Profit came in at Rs 2,155.75 Cr, up 28.46% from Rs 1,678.10 Cr. The YoY growth appears in all three lines for the July to September 2026 quarter on a consolidated basis.
Aurobindo Pharma Ltd (AUROPHARMA) Q2 Results FY27 announced on 4 November 2026, covering the company’s financial performance for the July to September 2026 quarter. The results date brought consolidated revenue of Rs 10,263.29 Cr and PAT of Rs 1,123.84 Cr. Aurobindo Pharma Q2 Results FY27 are reported on a consolidated basis, so every figure here comes from the consolidated results.
This Aurobindo Pharma Q2 Results article offers a results analysis of the financial highlights, business drivers, outlook and risks behind the numbers. It begins with the Financial Highlights table, which sets revenue, Operating Profit and net profit against the same quarter last year.
Click Here – Get Free Investment Predictions
Aurobindo Pharma Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 10263.29 Cr | Rs 8285.7 Cr | +23.87% YoY |
| Operating Profit | Rs 2155.75 Cr | Rs 1678.1 Cr | +28.46% YoY |
| Net Profit (PAT) | Rs 1123.84 Cr | Rs 848.13 Cr | +32.51% YoY |
Source: company filing for Aurobindo Pharma Q2 Results FY27, 4 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Aurobindo Pharma Q2 Results: What Stands Out
- Revenue: Consolidated revenue reached Rs 10,263.29 Cr against Rs 8,285.70 Cr a year earlier, which is a change of 23.87% in the quarter.
- Net profit: Net profit of Rs 1,123.84 Cr compares with Rs 848.13 Cr in the same quarter last year, showing YoY growth of 32.51%.
- Operating Profit: Operating Profit moved to Rs 2,155.75 Cr from Rs 1,678.10 Cr, a change of 28.46% on a year earlier.
- Risk headline: Return on equity was low at 9.93% in FY26, a figure investors may track.
- Next step: Aurobindo Pharma Q2 Results FY27 now move to the performance analysis, where the three reported lines are compared in more detail.
Aurobindo Pharma Q2 Results FY27: Performance Analysis
Aurobindo Pharma reported consolidated revenue of Rs 10,263.29 Cr for the July to September 2026 quarter, up 23.87% YoY from Rs 8,285.70 Cr. Net profit rose 32.51% YoY to Rs 1,123.84 Cr, and Operating Profit moved up 28.46% YoY to Rs 2,155.75 Cr. Together these quarterly results show growth in all three reported lines.
In this results analysis, revenue growth of 23.87% YoY sits alongside net profit growth of 32.51% and Operating Profit growth of 28.46%. Aurobindo Pharma Q2 Results FY27 therefore show all three lines rising against the Rs 10,263.29 Cr revenue base.
Investors following Aurobindo Pharma Q2 Results can compare these figures with the next set of quarterly results to see whether the YoY growth rates hold. Univest Screener users can track later disclosures for AUROPHARMA, which is where the results analysis turns to the business factors behind the quarter.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points first to revenue, which grew 23.9% year on year to Rs 10,263.29 Cr in the latest quarter. Aurobindo Pharma Q2 Results FY27 rest on this larger top line, from which Operating Profit and net profit are measured.
Net Profit Growth – Net profit rose 32.5% year on year to Rs 1,123.84 Cr. This profit growth sits alongside the revenue comparison, and the disclosed figures confirm the direction of net profit but do not establish the specific cause.
Consistent Revenue Rise – Revenue has risen in each of the last 4 quarters. This run is background to the YoY comparison, while net profit of Rs 1,123.84 Cr is the figure carried forward into the outlook.
FY27 Outlook After Aurobindo Pharma Q2 Results
Net profit of Rs 1,123.84 Cr gives one reference point for the FY27 outlook. Full-year FY27 results will depend on the quarters that follow and on disclosed sector conditions, so this results analysis treats the quarter as one data point rather than a full-year signal.
Aurobindo Pharma Q2 Results FY27 can be tracked against future filings on NSE and BSE, where later consolidated results will show how revenue growth of 23.87% YoY and net profit growth of 32.51% YoY compare with the next quarters. The risks that could affect that comparison come next.
Key Risks to Watch After Aurobindo Pharma Q2 Results FY27
Low Return on Equity
Return on equity was low at 9.93% in FY26. This annual ratio is background to the quarter, and later results will show whether it changes.
Declining Return on Equity
Return on equity declined to 9.93% in FY26 from 11.15% in FY25. This comparison forms part of the context investors can monitor alongside the consolidated results in the coming quarters.
Declining Return on Capital Employed
Return on capital employed declined to 12.76% in FY26 from 14.39% in FY25. This annual ratio is background to the quarter, and later filings will show whether it changes.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Aurobindo Pharma Q2 Results FY27 show consolidated revenue of Rs 10,263.29 Cr and net profit of Rs 1,123.84 Cr for the July to September 2026 quarter. Readers can compare Aurobindo Pharma Q2 Results with later quarterly results and with the consolidated results of the next filing on the Univest app. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Aurobindo Pharma Q2 Results FY27
What are Aurobindo Pharma Q2 Results FY27?
Ans. Aurobindo Pharma Q2 Results FY27 cover the July to September 2026 quarter, with consolidated revenue of Rs 10,263.29 Cr and net profit of Rs 1,123.84 Cr. Alongside this, the Quick Answer box summarises the three headline lines.
What is the results date for Aurobindo Pharma Q2 Results FY27?
Ans. The results date for Aurobindo Pharma Q2 Results FY27 is 4 November 2026, when the company declared its quarterly results. This results date also anchors the Financial Highlights table, which compares the quarter with the same period last year.
What revenue was reported in Aurobindo Pharma Q2 Results FY27?
Ans. Revenue in Aurobindo Pharma Q2 Results FY27 was Rs 10,263.29 Cr, compared with Rs 8,285.70 Cr a year earlier, which means revenue is the top line shown in the Financial Highlights table above.
What net profit was reported in Aurobindo Pharma Q2 Results FY27?
Ans. Net profit in Aurobindo Pharma Q2 Results FY27 was Rs 1,123.84 Cr against Rs 848.13 Cr in the same quarter last year, so the Key Takeaways section shows net profit alongside revenue and Operating Profit.
How much YoY growth did revenue show in Aurobindo Pharma Q2 Results FY27?
Ans. Revenue showed YoY growth of 23.87% in Aurobindo Pharma Q2 Results FY27, moving from Rs 8,285.70 Cr to Rs 10,263.29 Cr, while the Performance Analysis section compares this with the other two lines.
Did net profit rise or fall in Aurobindo Pharma Q2 Results?
Ans. Net profit rose in Aurobindo Pharma Q2 Results, up 32.51% YoY to Rs 1,123.84 Cr from Rs 848.13 Cr, so the Key Takeaways section lists it among the three reported lines with revenue and Operating Profit.
What was the Operating Profit in Aurobindo Pharma Q2 Results FY27?
Ans. Operating Profit in Aurobindo Pharma Q2 Results FY27 was Rs 2,155.75 Cr against Rs 1,678.10 Cr a year earlier, a change of 28.46%, which the Performance Analysis section compares with revenue and net profit.
Are Aurobindo Pharma Q2 Results consolidated results or standalone results?
Ans. Aurobindo Pharma Q2 Results are consolidated results, and every revenue, Operating Profit and net profit figure in this article is reported on that consolidated basis, so the Quick Answer box and tables use the same basis.
What business factors shaped Aurobindo Pharma Q2 Results FY27?
Ans. Revenue growth of 23.9% YoY, net profit growth of 32.5% YoY and revenue rising in each of the last 4 quarters are the factors behind Aurobindo Pharma Q2 Results FY27, as set out in Key Business Factors.
What are the key risks after Aurobindo Pharma Q2 Results FY27?
Ans. The key risks after Aurobindo Pharma Q2 Results FY27 are low return on equity of 9.93% in FY26, its decline from 11.15%, and the decline in return on capital employed to 12.76%, as detailed in Key Risks.
What is the outlook after Aurobindo Pharma Q2 Results?
Ans. The FY27 outlook after Aurobindo Pharma Q2 Results depends on the quarters that follow, so full-year net profit will be known only from later filings, as explained in the Outlook section of this results analysis.
Where can I find the complete Aurobindo Pharma Q2 Results FY27 data?
Ans. The complete Aurobindo Pharma Q2 Results FY27 data sits in the Financial Highlights table above and in the company’s filings on NSE and BSE, while the Univest app and Univest Screener help track AUROPHARMA.
